Biomedical & Biotech News
Clinical progress, drug development, platform technologies, and regulatory moves.
Genglycos allowed some patients to reduce the cornstarch needed to maintain blood glucose, but the accelerated approval is based on a surrogate endpoint; long-term benefits, hypoglycemia control, and tumor risk still require further study.
Aletta can locate a vein and collect blood on its own, but this does not mean healthcare without human staff: it is currently limited to adult outpatient use, and every procedure must still be initiated and supervised by a trained phlebotomist.
A research team screened thousands of computational designs to identify miniproteins capable of binding PD-L1, CD276, and VTCN1. Cell experiments showed that affinity alone is not enough to ensure effective CAR-T function; protein charge and surface expression are equally influential.
A Phase 3 trial showed that blocking Activin A can substantially reduce new heterotopic bone lesions in adults; the approval expands treatment options for the ultra-rare disease FOP, but long-term functional benefits and suitability for children remain to be confirmed.
A study in Nature shows that senescent cells not only sound the alarm through damaged mitochondria but also use acetyl-CoA to reshape chromatin and amplify pro-inflammatory secretion. Blocking citrate transport improved multiple measures in aged mice, but has not yet been tested in humans.
An atlas of human brain tissue identified a population of macrophages expressing the giant elastic protein TTN. These cells were increased in Alzheimer’s disease samples and showed features of aging, stress, and reduced cell communication, but “modulating tissue mechanics” remains only a therapeutic concept awaiting validation.
The ASPIRE trial combined endocrine therapy, a CDK4/6 inhibitor, and dual HER2 antibodies; 28 of 29 evaluable patients achieved clinical benefit within six months. Behind the impressive figures, however, remain limitations including the small sample size, lack of a control group, and hematologic toxicity.
Two cancer studies sought clues to treatment efficacy in patient blood and the source composition of cell products: ctDNA may help identify the risk of lung cancer recurrence, while removing certain immature NK cells could improve the consistency of off-the-shelf cell therapies.
The new agreement expands Jocasta’s exclusive rights to UCSF’s cognitive-therapy technology and settles its future payment obligations to UNITY; the real test will be whether the memory-improvement signal seen in primates can translate to humans.
A team from Genedata and Washington University used an automated workflow to identify a combination of plasma proteins that could complement p-tau217, and said the results were reproducible in an independent cohort; however, the proteins’ identities, performance data, and scope of clinical applicability have not yet been disclosed.
Two mouse studies show that repeatedly displaying more antigens on the surface of nanoparticles sustains memory B cells, long-lived plasma cells, and circulating antibodies more effectively than simply increasing single-site affinity, providing an adjustable physical parameter for HIV vaccine design.
An analysis of early-stage lung cancer tissue found that tumors treated with Aliya pulsed electric field ablation more often contained tertiary lymphoid structures with germinal centers, accompanied by B-cell and cytotoxic T-cell signals; however, the nonrandomized study cannot yet prove that patients benefit as a result.
In the full LUGANO analysis, the sustained-release intravitreal therapy DURAVYU failed to demonstrate noninferiority to aflibercept in visual acuity efficacy. Although a post hoc analysis excluding nine patients met the threshold, it cannot erase the fact that the primary endpoint was missed.